



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, India.

Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com

CIN: L24110TG1991PLC012471

Date: August 09, 2022

To,
National Stock Exchange of India Limited
BSE Limited

NSE Symbol - Granules; BSE Code- 532482

Dear Sir / Madam

Sub: Outcome of the Board meeting dated 9th August 2022.

Ref: Regulations 30 and 33 of the Listing Regulations.

Dear Sir,

The Board of Directors at their meeting has —

1. Approved the un-audited financial results (Standalone & Consolidated) for the first quarter ended on June 30, 2022, prepared under Indian Accounting Standards (Ind - AS).

Pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing the un-audited financial results (Standalone and Consolidated) of the Company for the first quarter ended on June 30, 2022.

We also enclose a copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations and the press release.

2. Approved the proposal to buy back up to 62,50,000 (Sixty two lakhs fifty thousand only) fully paid up equity shares having a face value of ₹ 1 (Rupee One Only) each (“**Equity Shares**” or “**Shares**”) representing up to 2.52% of the total number of equity shares in the paid-up equity share capital of the Company, at a price of ₹ 400/- (Rupees four hundred only) per Equity Share (“**Buyback Price**”) payable in cash for a maximum amount not exceeding ₹ 250 crores (Rupees two hundred and fifty crores only) (“**Buyback Size**”), representing 9.93% and 9.92% of the aggregate of the fully paid-up equity share capital and free reserves of the Company as per the latest audited standalone and consolidated financial statements of the Company as at March 31, 2022 respectively and is within the 10% limit of paid-up equity share capital and free reserves (including securities premium account) as per the latest audited standalone and consolidated financial statements of the Company as at March 31, 2022 respectively.

T. Chaitanya



The Buyback is proposed to be undertaken from the equity shareholders of the Company as on the record date i.e. August 23, 2022 (“**Record Date**”) on a proportionate basis, through the Tender Offer route in accordance with the provisions contained in the Securities and Exchange Board of India (BuyBack of Securities) Regulations, 2018 (“**Buyback Regulations**”) and the Companies Act, 2013 and rules made thereunder (the “**Buyback**”) (including any statutory modification(s) or re-enactment of the Act or Buy-back Regulations, for the time being in force).

The Buyback size does not include any expenses incurred or to be incurred for the Buyback like filing fees payable to the Securities and Exchange Board of India, brokerage, applicable taxes (such as income tax, buyback taxes, securities transaction tax, stamp duty and goods and service tax), advisors’ fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses.

3. Approved the formation of a buyback committee ("Buyback Committee") and delegated its powers to the Buyback Committee to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, usual or proper in connection with the Buyback.

The pre-buyback shareholding pattern of the Company as on June 30, 2022 is enclosed as Annexure A to this letter.

The meeting of the Board of Directors of the Company commenced at 11.00 A.M and concluded at 4.50 P.M.

This is for your information and record.

Thanking you,

FOR GRANULES INDIA LIMITED

T. Chaitanya

(CHAITANYA TUMMALA)
COMPANY SECRETARY &
COMPLIANCE OFFICER

Encl: As above




Annexure A

Granules India Limited
Pre-Buyback Shareholding Pattern as of June 30, 2022
(i.e. as per the latest shareholding pattern filed with Stock Exchanges)

Category of Shareholders	Numbers of Shareholders	Numbers of Shares	% of existing Share Capital
Promoter & Promoter Group	9	10,41,15,386	41.98
Total (A)	9	10,41,15,386	41.98
Institutions (Mutual Funds, Foreign Portfolio Investors, Financial Institutions/Banks)	160	6,48,88,552	26.16
Non-Institutions and Others (Individuals, NRIs, Bodies Corporates, IEPF etc.)	2,14,370	7,90,01,838	31.86
Total (B)	2,14,530	14,38,90,390	58.02
Grand Total (A+B)	2,14,539	24,80,05,776	100.00

Note: The Company has allotted 2,86,980 equity shares to fourteen employees of the Company under the Granules India Limited-Employee Stock Option Scheme 2009 on July 11, 2022. The trading approvals for these shares were received both from BSE Limited and the National Stock Exchange of India Limited on August 25, 2022.

The Post Buyback Shareholding Pattern of the Company shall be ascertained subsequently.




Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Granules India Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Granules India Limited (the "Company") for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

5. The comparative Ind AS financial information of the Company for the immediately preceding quarter ended March 31, 2022 and corresponding quarter ended June 30, 2021, included in these standalone Ind AS financial results, were reviewed/audited by the predecessor auditor and the Ind AS standalone financial statements of the Company for the year ended March 31, 2022, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those standalone financial information on July 27, 2021 and May 18, 2022 respectively.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

Navneet Kabra

per Navneet Kabra

Partner

Membership No.: 102328

UDIN: 22102328AOPGHHK4384



Place: Hyderabad

Date: August 09, 2022



GRANULES INDIA LIMITED
 Regd Office : 2nd Floor, 3rd Block, My Home Hub
 Madhapur, Hyderabad 500 081
 CIN:L24110TG1991PLC012471


Rs in lakhs

Statement of Un-Audited Standalone Results for the quarter ended June 30, 2022

Sl No.	Particulars	Quarter ended			Year ended
		30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
		Un-Audited	Audited (Refer Note 8)	Un-Audited	Audited
	Income				
1	Revenue from operations	92,135.70	91,284.82	73,211.59	323,843.66
2	Other income	454.84	427.91	735.57	1,751.00
3	Total income (1+2)	92,590.54	91,712.73	73,947.16	325,594.66
4	Expenses				
	(a) Cost of materials consumed	47,021.56	50,334.99	43,251.32	186,415.66
	(b) Changes in inventories of work in progress and finished goods	3,454.44	(1,730.76)	(4,158.13)	(10,641.06)
	(c) Employee benefit expenses	7,685.22	7,545.05	7,121.46	28,279.90
	(d) Finance costs	443.89	400.09	538.38	1,635.23
	(e) Depreciation and amortisation expense	3,459.94	3,168.28	3,149.57	12,616.09
	(f) Other expenses	14,308.44	14,538.68	11,993.40	55,324.27
	Total expenses	76,373.49	74,256.33	61,896.00	273,630.09
5	Profit before tax (3-4)	16,217.05	17,456.40	12,051.16	51,964.57
6	Tax expense				
	a) Current tax	3,945.78	4,417.61	3,119.66	13,350.68
	b) Deferred tax	(205.50)	114.37	(53.07)	(37.59)
	Total tax expense	3,740.28	4,531.98	3,066.59	13,313.09
7	Profit for the period (5-6)	12,476.77	12,924.42	8,984.57	38,651.48
8	Other comprehensive income/(loss) (net of tax)				
	(a) (i) items that will not be reclassified to profit or loss	-	(104.35)	-	(104.35)
	(ii) income tax on (i) above	-	26.26	-	26.26
	(b) (i) items that will be reclassified to profit or loss	300.58	724.56	(1,081.05)	1,913.86
	(ii) income tax on (i) above	(75.65)	(182.36)	272.08	(481.68)
	Total other comprehensive income/(loss), net of tax	224.93	464.11	(808.97)	1,354.09
9	Total comprehensive income (7+8)	12,701.70	13,388.53	8,175.60	40,005.57
10	Paid-up equity share capital (Face Value of Rs. 1/- per share)	2,480.06	2,480.06	2,476.75	2,480.06
11	Other equity				250,586.05
12	Earnings per share (Face value Rs. 1/- each)				
	(a) Basic (in Rs.)	5.03	5.21	3.63	15.60
	(b) Diluted (in Rs.)	5.02	5.20	3.61	15.55
		(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

Notes:

- The above un-audited standalone financial results for the quarter ended June 30, 2022 have been reviewed by the Audit Committee on August 08, 2022 and approved by the Board of Directors at their meeting held on August 09, 2022.
- The un-audited standalone financial results of the Granules India Limited ("Company") have been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Auditors of the Company have carried out Limited Review of the financial results for the quarter ended June 30, 2022.
- As the outbreak continues to evolve, the Company will continue to closely monitor any material changes to future economic conditions. Based on the assessment done by the management, there are no significant/material impact of COVID-19 on these results.
- The Company operates in one reportable business segment of Pharmaceutical products including ingredients and intermediaries.
- The Board of Directors of the Company in their meeting held on August 09, 2022 has approved buyback of 6,250,000 equity shares of Rs. 1/- each, representing 2.52% of total paid up equity share capital of the Company from the shareholders on a proportionate basis by way of a tender offer. The buyback price will be Rs 400 per equity share payable in cash for an aggregate amount not exceeding INR 25,000 lakhs in accordance with the provision of the Act and SEBI (Buyback of Securities) Regulation, 2018.
- The Code on Social Security, 2020 ("Code") relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the code becomes effective.
- The figures for the quarter ended March 31, 2022 is the balancing number between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which are subjected to limited review.
- The figures for the corresponding previous periods have been restated/regrouped wherever necessary, to make them comparable.



for and on behalf of the Board

(Signature)

Dr. Krishna Prasad Chigurupati
 Chairman and Managing Director

Place : Hyderabad
 Date : August 09, 2022

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Granules India Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Granules India Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following subsidiaries:
 - Granules USA Inc.
 - Granules Pharmaceuticals Inc.
 - Granules Consumer Health Inc.
 - Granules Europe Limited
 - Granules Life Sciences Private Limited
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
- 3 subsidiaries, whose unaudited interim financial results include total revenues of Rs 41,856.99 Lakhs, total net profit after tax of Rs. 955.07 Lakhs, total comprehensive income of Rs. 3,423.83 Lakhs, for the quarter ended June 30, 2022, as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's review reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

7. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:
- 2 subsidiaries, whose interim financial results and other financial information reflect total revenues of Rs 739.49 Lakhs, total net profit after tax of Rs. 533.44 Lakhs and total comprehensive income of Rs. 575.19 Lakhs, for the quarter ended June 30, 2022.

The unaudited interim financial results and other unaudited financial information of these subsidiaries have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

8. The comparative Ind AS financial information of the Group for the immediately preceding quarter ended March 31, 2022 and corresponding quarter ended June 30, 2021, included in these consolidated Ind AS financial results, were reviewed/audited by the predecessor auditor and the Ind AS consolidated financial statements of the Group for the year ended March 31, 2022, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those consolidated financial information on July 27, 2021 and May 18, 2022 respectively.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004


per Navneet Kabra

Partner

Membership No.: 102328

UDIN: 22102328AOPGNF7206



Place: Hyderabad

Date: August 09, 2022



GRANULES INDIA LIMITED
 Regd Office : 2nd Floor, 3rd Block, My Home Hub
 Madhapur, Hyderabad 500 081
 CIN:L24110TG1991PLC012471

Rs in lakhs

Statement of Un-Audited Consolidated Results for the quarter ended June 30, 2022

Sl No.	Particulars	Quarter ended			Year ended
		30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
		Un-Audited	Audited (Refer Note 9)	Un-Audited	Audited
	Income				
1	Revenue from operations	101,955.56	102,997.35	84,984.66	376,492.10
2	Other income	466.69	396.07	762.07	1,760.80
3	Total income (1+2)	102,422.25	103,393.42	85,746.73	378,252.90
	Expenses				
4	(a) Cost of materials consumed	53,696.07	55,584.52	46,006.37	203,642.00
	(b) Changes in inventories of work in progress and finished goods	(2,341.26)	(2,979.16)	(7,099.07)	(15,277.91)
	(c) Employee benefit expenses	10,872.10	10,815.67	9,538.96	40,137.69
	(d) Finance costs	693.69	636.17	679.32	2,321.07
	(e) Depreciation and amortisation expense	4,336.28	4,018.05	3,938.14	15,863.20
	(f) Other expenses	18,578.33	20,306.51	16,395.79	75,767.02
	Total expenses	85,835.21	88,381.76	69,459.51	322,453.07
5	Profit before tax (3-4)	16,587.04	15,011.66	16,287.22	55,799.83
6	Tax expense				
	a) Current tax	4,166.42	4,247.05	3,453.88	13,820.48
	b) Deferred tax	(336.23)	(335.04)	813.15	703.54
	Total tax expense	3,830.19	3,912.01	4,267.03	14,524.02
7	Profit for the period (5-6)	12,756.85	11,099.65	12,020.19	41,275.81
8	Other comprehensive income/(loss) (net of tax)				
	(a) (i) items that will not be reclassified to profit or loss	-	(104.35)	-	(104.35)
	(ii) income tax on (i) above	-	26.26	-	26.26
	(b) (i) items that will be reclassified to profit or loss	2,810.63	2,098.12	4.00	4,567.23
	(ii) income tax on (i) above	(75.65)	(182.36)	272.08	(481.68)
	Total other comprehensive income/(loss), net of tax	2,734.98	1,837.67	276.08	4,007.45
9	Total comprehensive income (7+8)	15,491.83	12,937.32	12,296.27	45,283.26
10	Profit for the period attributable to:				
	(i) Equity shareholders of the Company	12,756.85	11,099.63	12,020.19	41,275.79
	(ii) Non controlling interests	-	0.02	-	0.02
11	Total comprehensive income for the period attributable to:				
	(i) Equity shareholders of the Company	15,491.83	12,937.28	12,296.27	45,283.22
	(ii) Non controlling interests	-	0.04	-	0.04
12	Paid-up equity share capital (Face Value of Rs. 1/- per share)	2,480.06	2,480.06	2,476.75	2,480.06
13	Other equity excluding Non-controlling interest				256,173.23
14	Earnings per share (Face value Rs. 1/- each)				
	(a) Basic (in Rs.)	5.14	4.48	4.85	16.66
	(b) Diluted (in Rs.)	5.13	4.46	4.83	16.60
		(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)



Notes:

- The above un-audited consolidated financial results for the quarter ended June 30, 2022 have been reviewed by the Audit Committee on August 08, 2022 and approved by the Board of Directors at their meeting held on August 09, 2022.
- The un-audited consolidated financial results of Granules India Limited ("Company") and its subsidiaries (together referred to as "Group") have been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.




- 3 The Auditors of the Company have carried out Limited Review of the financial results for the quarter ended June 30, 2022.
- 4 The subsidiaries considered for the consolidation for the quarter ended June 30, 2022 are Granules USA Inc., Granules Pharmaceuticals Inc., Granules Europe Limited, Granules Life Sciences Private Limited and Granules Consumer Health, Inc. (Step-down subsidiary) (together referred to as "Subsidiaries").
- 5 The Group operates in one reportable business segment of Pharmaceutical products including ingredients and intermediaries.
- 6 The Board of Directors of the Company in their meeting held on August 09, 2022 has approved buyback of 6,250,000 equity shares of Rs. 1/- each, representing 2.52% of total paid up equity share capital of the Company from the shareholders on a proportionate basis by way of a tender offer. The buyback price will be Rs 400 per equity share payable in cash for an aggregate amount not exceeding INR 25,000 lakhs in accordance with the provision of the Act and SEBI (Buyback of Securities) Regulation, 2018.
- 7 As the outbreak continues to evolve, the Group will continue to closely monitor any material changes to future economic conditions. Based on the assessment done by the management, there are no significant/material impact of COVID-19 on these results.
- 8 The Code on Social Security, 2020 ("Code") relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the code will come into effect has not been notified. The Group will assess the impact of the Code when it comes into effect and will record any related impact in the period the code becomes effective.
- 9 The figures for the quarter ended March 31, 2022 is the balancing numbers between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which are subjected to limited review.
- 10 The figures for the corresponding previous periods have been restated/regrouped wherever necessary, to make them comparable.

Place : Hyderabad
Date : August 09, 2022 .



for and on behalf of the Board


Dr. Krishna Prasad Chigurupati
Chairman and Managing Director

Press Release

for Immediate Release

Granules India reports Income from operations at INR 1,020 Cr up 20% YoY, EBITDA at INR 212 Cr, EBITDA Margin at 21%; PAT at INR 128 Cr.

Hyderabad, India, August 09, 2022: Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended June 30, 2022.

Financial Summary (All numbers in INR Cr., except Margins)

CONSOLIDATED FINANCIALS	Q1FY23	Q4FY22	Growth (QoQ)	Q1FY22	Growth (YoY)
Income from Operations	1,020	1,030	(1%)	850	20%
EBITDA	212	193	10%	201	5%
EBITDA %	21%	19%		24%	
PAT	128	111	15%	120	6%
Net Profit Margin	13%	11%		14%	

Financial and Business Summary for Q1FY23:

- Revenue for Q1FY23 stood at INR 1,020Cr, growth of 20% YoY across all geographies and segments. Revenue share from Europe increased to 22.5% when compared to 16.8% YoY.
- Revenue share of non-core molecules stood at 18% Q1FY23 when compared to 17% in Q1FY22, in line with our long-term strategy.
- During the quarter we filed five ANDAs, two US DMFs, and received one US, one EU and one Canadian approval.
- Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI) and Finished dosages contributes 23%, 23% and 54% of total revenue respectively.
- The Company has acquired capital assets of a small Biotech Company to gain ready platform for biotechnology focused research and manufacturing.
- The Company has received approval from the Department of Pharmaceuticals (DOP) under Production Linked Incentive (PLI) Scheme to manufacture Dicyandiamide (DCDA).
- Board of directors approved a buyback of 6,250,000 equity shares at a price of Rs. 400 per equity share for an aggregate maximum amount of Rs.250 Crs.

Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “As we enter FY23, we are excited about Granules 2.0 strategy. While the overall geopolitical environment is far from being normal, we must take these in our stride and look forward executing our strategy without any flaw. I feel confident when I see the transformation taking place with the relentless effort put in by our employees to ensure that we continue to grow and demonstrate excellence and differentiation in whatever we do. US pricing pressure, increased cost of raw materials, solvents and Logistics are the challenges and continue performing with sustained growth and predictability.”

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US and UK. The Company has 7 manufacturing facilities out of which 6 are in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Safe Harbor

This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Granules India Ltd., its directors and any of the affiliates or employee is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:	
Krishna Raghunathan 040-69043573 VP – Finance and Investor Relations krishna.raghunathan@granulesindia.com	Chaitanya Tummala 040-69043614 Company Secretary chaitanya.tummala@granulesindia.com